Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493109 | 0.89 | KDM1A (0.57) | KDM1ALTA4HRAB9AKCNH2KDM4E | |
| SCHEMBL5483694 | 0.86 | SCN3A (0.58) | LTA4HKCNH2PARP10 | |
| SCHEMBL5482943 | 0.83 | TACR1 (0.47) | KDM1ALTA4HKDM4EKMT2ASMN1; SMN2 | |
| Carbamic Acid SCHEMBL5481170 | 0.81 | KDM4E (0.65) | KDM1ARAB9AHTR2CHTR2BKDM4E | |
| SCHEMBL6064341 | 0.77 | KCNH2 (0.52) | KDM1AKCNH2PARP10 | |
| SCHEMBL5481350 | 0.77 | KCNH2 (0.52) | KDM1AKCNH2PARP10 | |
| SCHEMBL5481355 | 0.77 | KCNH2 (0.52) | KDM1AKCNH2PARP10 | |
| SCHEMBL5481360 | 0.77 | KCNH2 (0.52) | KDM1AKCNH2PARP10 | |
| SCHEMBL372599 | 0.77 | HPGD (0.51) | KDM1ALTA4HSMN1; SMN2 | |
| SCHEMBL5394785 | 0.77 | HPGD (0.51) | KDM1ALTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | claimed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | claimed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | claimed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | disclosed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | disclosed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | disclosed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066688-A1 | Cyclopentyl derivatives | HCN3, RYR2, KCNN3 | KDM1A 4309/4885LTA4H 2084/4885RAB9A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.